The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
- Author:
Bum Jun KIM
1
;
Chi Hoon MAENG
;
Bhumsuk KEAM
;
Young-Hyuck IM
;
Jungsil RO
;
Kyung Hae JUNG
;
Seock-Ah IM
;
Tae Won KIM
;
Jae Lyun LEE
;
Dae Seog HEO
;
Sang-We KIM
;
Keunchil PARK
;
Myung-Ju AHN
;
Byoung Chul CHO
;
Hoon-Kyo KIM
;
Yoon-Koo KANG
;
Jae Yong CHO
;
Hwan Jung YUN
;
Byung-Ho NAM
;
Dae Young ZANG
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2025;57(1):39-46
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to review IITs conducted by KCSG and quantitatively evaluate the survival and financial benefits of IITs for patients.
Materials and Methods:We reviewed IITs conducted by KCSG from 1998 to 2023, analyzing progression-free survival (PFS) and overall survival (OS) gains for participants. PFS and OS benefits were calculated as the difference in median survival times between the intervention and control groups, multiplied by the number of patients in the intervention group. Financial benefits were assessed based on the cost of investigational products provided.
Results:From 1998 to 2023, KCSG conducted 310 IITs, with 133 completed and published. Of these, 21 were included in the survival analysis. The analysis revealed that 1,951 patients in the intervention groups gained a total of 2,558.4 months (213.2 years) of PFS and 2,501.6 months (208.5 years) of OS, with median gains of 1.31 months in PFS and 1.58 months in OS per patient. When analyzing only statistically significant results, PFS and OS gain per patients was 1.69 months and 3.02 months, respectively. Investigational drug cost analysis from six available IITs indicated that investigational products provided to 252 patients were valued at 10,400,077,294 won (approximately 8,046,481 US dollars), averaging about 41,270,148 won (approximately 31,930 US dollars) per patient.
Conclusion:Our findings, based on analysis of published research, suggest that IITs conducted by KCSG led to survival benefits for participants and, in some studies, may have provided financial benefits by providing investment drugs.
